Absci Corporation

1 day ago · defenseworld.net

Valneva (NASDAQ: VALN - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation. Profitability This table compares Valneva and Absci's net margins,

5 days ago · seekingalpha.com

Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

14 days ago · seekingalpha.com

Absci Corporation is upgraded to “Buy” following positive interim Phase 1 data for ABS-201 in androgenetic alopecia [AGA]. ABS-201 demonstrated an excellent PK profile, enabling infrequent dosing [2–3 injections per 6 months] and strong safety/tolerability in SAD cohorts. Upcoming catalysts include 13-week interim proof-of-concept data in 2H 2026 and 26-week topline results in early 2027 for ABS-201 in AGA.

21 days ago · globenewswire.com

VANCOUVER, Wash. and NEW YORK, Sept.

1 month ago · zacks.com

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

1 month ago · seekingalpha.com

Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript

1 month ago · marketbeat.com

Absci NASDAQ: ABSI outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis, while reporting a larger cash balance following a June equity offering and strategic investment from Eli Lilly.

1 month ago · globenewswire.com

Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half of 2028 VANCOUVER, Wash. and NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended June 30, 2026.

1 month ago · 247wallst.com

Anthropic is preparing what could be the largest IPO of 2026, and it's telling investors the pitch goes well beyond chatbots. According to the Wall Street Journal, "Anthropic is targeting a public debut in September or early October, people familiar with its plans said." In those same meetings, the company told some investors that it... The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It's Not Tech)

2 months ago · zacks.com

Here is how Absci Corporation (ABSI) and Acadia Healthcare (ACHC) have performed compared to their sector so far this year.